Upstream Bio, Inc.
Developing a monoclonal antibody for severe inflammatory and respiratory diseases.
UPB | US
Overview
Corporate Details
- ISIN(s):
- US91678A1079
- LEI:
- Country:
- United States of America
- Address:
- 890 WINTER STREET, SUITE 200, 2451 WALTHAM
- Website:
- https://upstreambio.com/
- Sector:
- Manufacturing
- Industry:
- Manufacture of pharmaceuticals, medicinal chemical and botanical products
Description
Upstream Bio, Inc. is a clinical-stage biotechnology company focused on developing novel treatments for inflammatory diseases, with an initial emphasis on severe respiratory disorders. The company's lead product candidate is verekitug, a monoclonal antibody designed to target the thymic stromal lymphopoietin (TSLP) receptor. By inhibiting this key upstream driver of pro-inflammatory signaling, Upstream Bio aims to disrupt the pathway implicated in numerous inflammatory conditions. The company is advancing verekitug through clinical trials to evaluate its potential in treating severe asthma, chronic rhinosinusitis with nasal polyps (CRSwNP), and chronic obstructive pulmonary disease (COPD).
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| No filings match the current criteria. | |||||
Automate Your Workflow. Get a real-time feed of all Upstream Bio, Inc. filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for Upstream Bio, Inc.
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for Upstream Bio, Inc. via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
Peer Companies
